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The Chk2 protein kinase protects genome integrity by promoting cell cycle arrest or apoptosis in response
to DNA double-strand breaks, and Chk2 mutations are found in both familial and sporadic cancers. Exposure
of cells to ionizing radiation (IR) or radiomimetic drugs induces Chk2 phosphorylation by ATM, followed by
Chk2 oligomerization, auto-/transphosphorylation, and activation. Here we demonstrate that Chk2 is ubiq-
uitinated upon activation and that this requires Chk2 kinase activity. Serine 379 (S379) was identified as a
novel IR-inducible autophosphorylation site required for ubiquitination of Chk2 by a Cullin 1-containing E3
ligase complex. Importantly, S379 was required for Chk2 to induce apoptosis in cells with DNA double-strand
breaks. Thus, auto-/transphosphorylation of S379 is required for Chk2 ubiquitination and effector function.
The integrity of chromosomal DNA is continuously moni-
tored throughout the cell division cycle. DNA damage acti-
vates signaling pathways called checkpoints that induce cell
cycle arrest or apoptosis. Defects in checkpoint control can
result in genomic instability and cancer predisposition (15).
The Chk2 protein kinase is a key mediator of the DNA damage
checkpoint that responds to DNA double-strand breaks
(DSBs) (7, 8, 31). DNA DSBs induce the activation of ATM
(ataxia telangiectasia mutated), which subsequently phosphor-
ylates Chk2 on T68 within the N-terminal SQ/TQ cluster do-
main (3, 32, 33). T68 phosphorylation is required for efficient
oligomerization and subsequent auto-/transphosphorylation of
Chk2 at other regulatory sites, including T383/387, S456, and
S516 (2, 22, 25, 41, 53).
Heterozygous germ line mutations in CHK2 are associated
with a p53-independent variant form of the Li-Fraumeni her-
itable cancer predisposition syndrome (6). Cells derived from
Chk2-deficient mice exhibit defects in their ability to delay
entry into S phase, sustain a G2 cell cycle arrest, and undergo
apoptosis in response to DNA damage (16, 46). These effects
have been attributed to a failure of p53 to be properly modified
in Chk2-deficient cells. Chk2 phosphorylates p53 on S20 in
vitro. S20 phosphorylation has been proposed to mediate p53
stabilization by preventing interaction of p53 with its negative
regulator MDM2; however, the exact function for this phos-
phorylation event remains unclear (9, 10, 17, 20, 42, 52). In
addition to p53, additional substrates of Chk2 include Brca1,
MDMX2, PML, p73, and E2F1 (11, 26, 37, 45, 47, 54).
The covalent modification of cellular proteins by ubiquitin is
best known for its role in mediating their proteasome-depen-
dent proteolysis. However, recent studies have demonstrated
that ubiquitination can also modify the enzymatic activity, traf-
ficking, localization, and binding partners of the modified pro-
tein (21, 40). Here we show that Chk2 phosphorylates itself on
S379 in response to DNA damage. This in turn, facilitates
Chk2 ubiquitination by an E3 ligase complex containing Cullin
1 (Cul 1). Ubiquitination of Chk2 did not detectably alter its
stability. Importantly, S379 was shown to play an important
role in the ability of Chk2 to induce apoptosis in cells with
DNA DSBs. Thus, ubiquitination of Chk2 may regulate Chk2
effector function.
MATERIALS AND METHODS
Antibodies and Western blotting. Endogenous Chk2 was detected either with
a mouse monoclonal antibody (Upstate, clone 7) or with a rabbit polyclonal
antibody raised against bacterially produced glutathione S-transferase (GST)–
Chk2 (14). Flag3-Chk2 fusion proteins were precipitated with anti-Flag M2
antibody-agarose affinity gel (Sigma Chemical Co.) and detected by Western
blotting with anti-Flag M2 monoclonal antibody (Sigma Chemical Co.). Myc3-
Chk2 fusion proteins were immunoprecipitated with anti-Myc mouse monoclo-
nal 9E10-conjugated agarose (Santa Cruz Biotechnology) and detected by West-
ern blotting with anti-c-Myc A14 rabbit polyclonal antibody (Santa Cruz
Biotechnology). Bound primary antibodies were detected with horseradish per-
oxidase (HRP)-conjugated goat anti-mouse (ICN/CAPPEL), HRP-goat anti-
mouse (Jackson Laboratories), HRP-donkey anti-goat (Santa Cruz Biotechnol-
ogy), or HRP-goat anti-rabbit (Zymed) secondary antibodies, and proteins were
visualized using ECL (GE Healthcare Life Sciences). Antibodies specific for
Chk2 phosphorylated on S379 were generated by immunization of rabbits with
the phosphopeptide CILGET-pS-LMR coupled to keyhole limpet hemocyanin.
Antibodies specific for Chk2 phosphorylated on T68, T383/387, and S516 have
been described previously (41). Ubiquitination assays carried out in vitro were
probed with a ubiquitin-specific antibody (P4D1; Santa Cruz Biotechnology).
Cell culture and treatment of cells with DNA-damaging agents. HEK-293 and
U2OS cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% bovine growth serum, 100 units/ml (each) penicillin and
streptomycin, and 1 mM L-glutamine (complete DMEM). Chk2 null mouse
embryo fibroblasts (MEFs) (16) were maintained in DMEM supplemented with
10% fetal bovine serum, 100 units/ml penicillin and streptomycin, 2 mM L-
glutamine, and 0.1 mM nonessential amino acids. In some cases, cells were
exposed to 10 Gy from a 60Co source or were treated with complete DMEM
containing 20 M etoposide (VP16; Sigma Chemical Company).
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Plasmids. pET15b Chk2-WT (wild type) and -D368N; pcDNA3-Myc3Chk2-WT
and -D368N; and pcDNA3-Flag3Chk2-WT, -D368N, -T68A, -T383/387A, and
-S516A have been described previously (41). pET15b-Chk2-S379A was gener-
ated by site-directed mutagenesis of pET15b-Chk2-WT using the QuikChange
site-directed mutagenesis kit (Stratagene) and the primers 5-TCCAAGATTTT
GGGAGAGACCGCTCTCATGAGAACCT-3 (forward) and 5-GGTTCCAC
ATAAGGTTCTCATGAGAGCGGTCTCTCCC-3 (reverse). The same prim-
ers were used to generate pcDNA3-Flag3-Chk2-S379A and pcDNA3-Myc3-
Chk2-S379A by site-directed mutagenesis of pcDNA3-Flag3-Chk2-WT and
pcDNA3-Myc3-Chk2-WT vectors, respectively. pcDNA5/FRT-Myc3-Chk2-WT
was generated by inserting the KpnI/XhoI fragment of pcDNA3-Myc3-Chk2-WT
encoding Myc3-Chk2 into the corresponding sites of pcDNA5/FRT (Invitrogen).
pcDNA5/FRT-Myc3-Chk2-D368N and pcDNA5/FRT-Myc3-Chk2-S379A were
generated in a similar manner. Sequences of all mutants were verified by DNA
sequencing. Plasmids encoding Myc-tagged Cullin proteins and dominant-nega-
tive forms of Cul 1 and Cul 3 have been described previously (12, 36, 43). The
first 393 amino acids of Cul 4B were cloned into the KpnI/XhoI-digested
pcDNA3-Flag3 vector to generate a dominant-negative Cul 4B protein.
To generate pcDNA3-TAP-Chk2 constructs, pcDNA3-Flag3 was used to gen-
erate the backbone pcDNA3-TAP vector by sequential cloning of the protein A
binding domain followed by two TEV protease cleavage sites upstream of the
Flag3-coding sequence. Sequences encoding the protein A binding domain were
amplified by PCR using the primers 5-CCCAAGCTTATGGCGATTAAGGG
TGAAGCTCA and 5-GGGGTACCTTCTTTGCTCACCGAAGGATCG. The
product was cloned into HindIII/KpnI-digested pcDNA3-Flag3. Oligonucleo-
tides encoding the two TEV protease cleavage sites (5-GGAATTCCGAAAA
TCTATATTTTCAAGGTACTGCTTCTCAGCACGAAAATCTATATTTTC
AAGGTGAACTAGATATCCAG and its complement) were annealed and
cloned into EcoRI/EcoRV-digested pcDNA3-protein A-Flag3, positioning the
TEV cleavage sites between the protein A binding domain and the Flag3-coding
sequence to generate pcDNA3-TAP-Chk2 (WT, D368N, and S379A), which was
then cloned into BsiWI/EcoRV-digested pcDNA3-TAP.
Chk2 ubiquitination in vivo. HEK-293 cells were cotransfected with plasmids
encoding Flag3-tagged Chk2 (WT and mutants) and His6 Myc-ubiquitin using
Superfect reagent (Qiagen). At 42 h posttransfection, cells were washed once
with ice-cold phosphate-buffered saline and lysed in mammalian cell lysis buffer
(MCLB) (50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 5 mM EDTA, 0.5% Nonidet
P-40, and 2 mM dithiothreitol [DTT]) containing 1 mM sodium orthovanadate,
10 mM -glycerophosphate, 1 M microcystin, 2 mM phenylmethylsulfonyl
fluoride (PMSF), 10 g/ml aprotinin, and 5 g/ml leupeptin. Ectopically ex-
pressed Chk2 was immunoprecipitated with anti-Flag M2 monoclonal antibody
prebound to agarose (Sigma Chemical Co.). Immunoprecipitates were subjected
to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
transferred to nitrocellulose, and immunoblotted with polyclonal antibodies spe-
cific for either the Myc epitope (Santa Cruz Biotechnology) or Chk2 (14).
Stability of endogenous and ectopic Chk2. Asynchronously growing HEK-293
cells were treated with 20 g/ml cycloheximide (Sigma Chemical Co.) in com-
plete DMEM. Cells were then either mock irradiated or exposed to 10 Gy
ionizing radiation (IR) and harvested at various times post-IR. Cell lysates were
prepared in MCLB, resolved by SDS-PAGE, and transferred to nitrocellulose.
For phosphatase treatment, cells were lysed in buffer containing 50 mM Tris-HCl
pH 8.0, 150 mM NaCl, 0.5% NP-40, 2 mM DTT, 1 mM PMSF, 5 g/ml leupeptin,
and 10 g/ml aprotinin. Cleared lysates were incubated with  phosphatase
(1,200 units per mg of total cellular protein; New England Biolabs) at 30°C for
1 h prior to SDS-PAGE and Western blotting. Proteins were visualized using the
ECL reagent (GE Healthcare Life Sciences), and densitometry analysis was
performed using Image J software (1).
HEK-293 cells were transfected with plasmids encoding Flag3-tagged Chk2
(WT, D368N, and S379A) using Superfect transfection reagent (Qiagen). At 48 h
posttransfection, cells were treated with 20 g/ml cycloheximide and harvested at
various time points. Cell lysates were prepared in MCLB and analyzed by West-
ern blotting using anti-Flag antibody. Densitometry analysis was performed as
described above.
Two-dimensional phosphopeptide mapping. HEK-293 cells (1.5  106) were
either mock transfected or transfected with plasmids encoding Flag3-tagged
wild-type and mutant forms of Chk2 using Superfect transfection reagent (Qia-
gen). At 42 hours posttransfection, cells were incubated in phosphate-free
DMEM containing 2.5 mCi of 32P-labeled inorganic phosphate per ml (Perkin-
Elmer Life Sciences) and 25 M VP16 for 2 h. Cells were washed once with
ice-cold phosphate-buffered saline and lysed in MCLB containing 2 mM DTT, 1
M microcystin, 1 mM PMSF, 5 g/ml leupeptin, and 10 g/ml aprotinin.
Ectopically expressed Chk2 was immunoprecipitated with anti-Flag M2 mono-
clonal antibody prebound to agarose (Sigma Chemical Co.). Immunoprecipitates
were subjected to SDS-PAGE on an 8% polyacrylamide gel, and proteins were
transferred to nitrocellulose. Radiolabeled Chk2 was digested in a solution
containing 0.2 mg/ml trypsin (Roche Applied Science) in 50 mM ammonium
bicarbonate for 15 h. Tryptic phosphopeptides were separated in the first dimen-
sion by electrophoresis and in the second dimension by ascending chromatogra-
phy in 200 ml of buffer consisting of 75 ml n-butanol, 50 ml pyridine,15 ml acetic
acid, and 60 ml water (48).
Purification of bacterially produced Chk2 protein. Escherichia coli strain BL21
was transformed with pET15b plasmids encoding His6-Chk2-WT, His6-Chk2-
D368N, and His6-Chk2-S379A. Cultures were grown at 37°C to an optical density
at 600 nm of 0.5, at which time isopropyl-1-thio-D-galactopyranoside (IPTG) was
added to a final concentration of 0.5 mM and protein expression was induced at
37°C for 4 h. Bacterial pellets were resuspended in NP-40 lysis buffer (50 mM
Tris-HCl [pH 8.0], 150 mM NaCl, 5 mM EGTA, 0.5% NP-40) supplemented
with protease inhibitors (2 mM PMSF, 0.15 unit/ml of aprotinin, and 20 M
leupeptin), 1 M microcystin, and 2 mg/ml lysozyme and then rocked at 4°C for
30 min. Cells were lysed by sonication (50% duty cycle for 20 bursts). Lysates
were clarified by centrifugation (14,000  g for 15 min). His6-tagged proteins
were precipitated by incubation with Ni2-nitrilotriacetic acid agarose (Qiagen)
for 2 h at 4°C. Precipitated proteins were washed two times in NP-40 lysis buffer
and two times in lysis buffer without NP-40. Bound proteins were eluted in
elution buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1 mM DTT) containing
100 mM imidazole and dialyzed overnight at 4°C in dialysis buffer (50 mM
Tris-HCl [pH 7.4], 2 mM DTT). Purified His-Chk2 proteins were concentrated
using Vivaspin columns (Vivascience, Inc.).
Generation of U2OS/FRT stables lines. The Flp-In system (Invitrogen) was
used in order to create U2OS cell lines that stably express Myc3-tagged Chk2
proteins. U2OS cells were first stably transfected with pFRT/lacZeo using Lipo-
fectamine 2000 (Invitrogen), and transfected colonies were selected in medium
containing 50 g/ml Zeocin (Invitrogen). Single colonies were grown up, their
-galactosidase activity was measured, and Southern analysis was performed to
determine the number of FLP recombination target (FRT) sites inserted into the
genome. The clone selected, U2OS/FRT16, had only one FRT site inserted into
the genome. This clone was then cotransfected with pOG44, a vector for tran-
sient transfection of the Flp recombinase, and with pcDNA5/FRT-Myc3-Chk2-
WT, -Myc3-Chk2-D368N, or -Myc3-Chk2-S379A using Lipofectamine 2000. The
pcDNA5/FRT-Myc3-Chk2 vector contains the coding region for Chk2 (wild type
or point mutants) and possesses an FRT site for homologous recombination.
After insertion of the Chk2 gene into the FRT site, Chk2 transcription is driven
by the human cytomegalovirus immediate-early enhancer/promoter. The
pcDNA5/FRT vector also carries a hygromycin resistance gene to allow for
selection of stable cells in 100 g/ml hygromycin (Invitrogen). Homologous
recombination of Myc3-Chk2 into the FRT site inactivates the lacZ-Zeocin
fusion gene, and stable cells are no longer Zeocin resistant. Hygromycin-resistant
colonies were grown as pools in DMEM containing 10% fetal bovine serum, 100
g/ml hygromycin, 100 units/ml (each) penicillin and streptomycin, and 1 mM
L-glutamine.
Phosphorylation experiments with Chk2 null MEFs. Chk2 null MEFs were
transfected with Flag3-Chk2 (WT, D368N, or S379A). At 44 h posttransfection,
cells were harvested and lysed in MCLB. Lysates were immunoprecipitated with
anti-Flag agarose for 2 h at 4°C. Immunoprecipitates were subsequently washed
three times with MCLB. Bound proteins were released by boiling in SDS loading
buffer, and then each immunoprecipitate was divided equally into three for
resolution by SDS-PAGE. The resulting SDS gels were transferred to nitrocel-
lulose and visualized with the indicated anti-phospho-Chk2 antibodies. The anti-
phospho-Chk2 blots were then stripped and reprobed with an antibody specific
for the Flag epitope.
Chk2 kinase assays. U2OS/FRT16-Myc3-Chk2-WT, -D368N, and -S379A sta-
ble lines were either mock or gamma irradiated with 10 Gy IR. At 30 min
post-IR, cells were harvested and lysed in MCLB containing protease and phos-
phatase inhibitors. Chk2 proteins were immunoprecipitated with anti-c-Myc aga-
rose. The immunoprecipitates were washed three times with MCLB and once
with incomplete kinase buffer (50 mM Tris HCl [pH 7.4], 1 mM DTT, 10 mM
MgCl2). Kinase reactions with 50-microliter reaction mixtures were carried out in
the presence of incomplete kinase buffer containing 10 M ATP, 10 Ci of
[32P]ATP (Perkin-Elmer Life Sciences), and 5 g of soluble GST-Cdc25C(200–
256) (34). Reaction mixtures were incubated at 30°C for 6 min and resolved by
SDS-PAGE. Incorporated counts were quantified using a Molecular Dynamics
Storm Imager (GE Healthcare Life Sciences). In the figures, error bars represent
average counts of triplicate reactions performed for each mutant.
Etoposide-induced apoptosis. Conditions for etoposide-induced apoptosis
have been described previously (45). U2OS/FRT16-Myc3Chk2-WT, -D368N,
and -S379A stable lines as well as parental U2OS/FRT16 cells were exposed to
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FIG. 1. Chk2 autophosphorylation on S379 regulates ubiquitination. (A) HEK-293 cells were transfected with plasmids encoding Flag3-Chk2
(WT and D368N) and Myc-tagged ubiquitin. At 42 h posttransfection, cells were treated with MG132 for 2 h, and Chk2 proteins were
immunoprecipitated using an antibody specific for the Flag epitope. Ubiquitinated proteins were visualized by immunoblotting with antibodies
specific for either Myc (top left panel) or Chk2 (top right panel). Precipitated Flag3-Chk2 was detected with antibodies specific for Flag (bottom
left panel) or Chk2 (bottom right panel). (B to D) Asynchronously growing HEK-293 cells expressing Flag3-Chk2-WT (B), Flag3-Chk2-D368N (C),
or Flag3-Chk2-S379A (D) were incubated with
32P-labeled inorganic phosphate in the presence of 25 M VP16. Radiolabeled Chk2 proteins were
digested with trypsin, and peptides were subjected to two-dimensional phosphopeptide mapping. The arrow in panel D denotes the absence of a
phosphopeptide that is present in the map of wild-type Chk2. (E) Alignment of sequences inclusive of and surrounding S379 in the indicated Chk2
orthologs. The asterisk denotes S379 in human Chk2 and conserved residues in other orthologs. (F) HEK-293 cells were transfected with plasmids
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20 M etoposide for the indicated time periods. Cells were harvested at 24 and
48 h after treatment and fixed in 70% ethanol. Cells were then stained with 30
g/ml of propidium iodide for 30 to 60 min and analyzed by flow cytometry using
a Becton-Dickinson FACScan. The data were analyzed by using CELLQUEST
software.
Purification of TAP-tagged Chk2 proteins. Expression plasmids encoding
TAP-tagged Chk2 proteins were transfected into HEK-293 cells using Superfect
transfection reagent (Qiagen) for 48 h according to the manufacturer’s instruc-
tion. Cells were lysed, and clarified lysates were incubated with rabbit immuno-
globulin G (IgG) agarose (Sigma Chemical Co.) at 0.5 g IgG agarose per mg of
total cell protein for 3 h at 4°C. Bound Chk2 proteins were washed three times
with MCLB followed by three times with TEV cleavage buffer (10 mM Tris-HCl
[pH 8.0], 150 mM NaCl, 0.1% NP-40, 0.5 mM EDTA, 1 mM DTT). Washed
beads were resuspended in 100 l TEV cleavage buffer containing 10 units of
TEV protease (Invitrogen) and incubated at 4°C overnight. Reaction mixtures
were centrifuged at 250  g for 3 min. Supernatants were removed and placed in
a fresh tube, and pelleted IgG beads were suspended in 500 l of MCLB,
followed by centrifugation at 250  g for 3 min. The resulting supernatants were
combined with the first TEV elution, and then 50 l of anti-Flag agarose was
added and the mixture was incubated at 4°C for 2 h. Reaction mixtures were
centrifuged at 250  g for 3 min, and the precipitated Flag beads were washed
five times with MCLB. Precipitates containing Flag3-Chk2 proteins were sus-
pended in 100 l of MCLB containing 0.35 mg/ml of Flag3 peptides (Peptide
Synthesis Core Facility at Tufts University) for 1 h at 4°C to elute the Flag-tagged
proteins.
Ubiquitination assays in vitro. Ubiquitin ligase reactions were carried out in
vitro as described previously (35). Purified ubiquitin, human recombinant E1
ubiquitin-activating enzyme, and E2 (UbcH5c) enzyme were purchased from
Boston Biochem. TAP-tagged Chk2 proteins were purified as described above.
Cullin ligase complexes were isolated from HEK-293 cells transfected with plas-
mids encoding Myc-Cul 1, Myc-Cul 3, or Myc-Cul 4B using Myc-agarose (Santa
Cruz Biotechnology). Immunocomplexes were washed three times with MCLB
and twice with ubiquitin reaction buffer (50 mM Tris-HCl [pH 7.4], 5 mM MgCl2,
2 mM NaF, 10 nM okadaic acid, 2 mM ATP, and 0.6 mM DTT). Washed
immunocomplexes were added to a ubiquitin ligation reaction mixture (final
volume, 30 l) containing 15 g purified TAP-tagged Chk2 proteins, 0.75 g
ubiquitin, 60 ng E1, and 300 ng E2 in ubiquitin reaction buffer. Reaction mixtures
were incubated at 37°C for 60 min, reactions were terminated by addition of SDS
loading buffer, mixtures were boiled for 5 min, and products were resolved by
SDS-PAGE followed by Western blotting.
RESULTS
Autophosphorylation of Chk2 on S379 is required for Chk2
ubiquitination. Following DNA damage, Chk2 oligomerizes in
a phosphorylation-dependent manner, a process that ulti-
mately results in its full activation (2, 41, 53). Previously we
demonstrated that Chk2 oligomerizes and auto-/transphosphor-
ylates in the absence of any exogenous DNA damage when
expressed at high levels either in HEK-293 cells or in bacteria
(41). As seen in Fig. 1A, a slower electrophoretic form of Chk2
was observed when wild-type (lane 1) but not kinase-inactive
(lane 2) Chk2 was produced in HEK-293 cells, and this is due
to Chk2 oligomerization followed by auto-/transphosphoryla-
tion (41). Strikingly, wild-type but not kinase-inactive Chk2
was ubiquitinated when coproduced with Myc-tagged ubiquitin
in these cells. This was demonstrated using antibodies that
recognize either the tagged form of ubiquitin (Fig. 1A, left) or
Chk2 itself (Fig. 1A, right). These results demonstrate that
Chk2 ubiquitination requires Chk2 kinase activity.
To identify phosphorylation sites that might be required for
Chk2 ubiquitination, HEK-293 cells were transfected with
Flag3-Chk2 constructs, treated with etoposide (VP16), and ra-
diolabeled with [32P]orthophosphate. The Flag3-tagged pro-
teins were immunoprecipitated and used to generate tryptic
phosphopeptide maps. Wild-type Chk2 gave rise to seven re-
solvable phosphopeptides (labeled 1 to 7 in Fig. 1B). Interest-
ingly, all seven were absent when 32P-labeled kinase-inactive
Chk2 (Chk2-D368N) was subjected to two-dimensional phos-
phopeptide mapping (Fig. 1C). These results demonstrate that
phosphopeptides 1 to 7 require the kinase activity of Chk2. The
identity of individual phosphopeptides was determined by
phosphoamino acid analysis and site-directed mutagenesis.
Mutation of serine 379 to alanine (S379A) resulted in loss of
phosphopeptide 3 (Fig. 1D), whereas mutation of serine 516 to
alanine (S516A) resulted in loss of phosphopeptide 7 (data not
shown). Since the NH2 terminus of Chk2 lacks trypsin cleavage
sites from amino acid 3 to 95, phosphopeptides from this re-
gion are not resolvable using this approach and are repre-
sented on the two-dimensional maps as unresolved phos-
phopeptides along the x axis (Fig. 1B to D). S379 was also
identified as a Chk2 autophosphorylation site by mass spec-
troscopy (23). Interestingly, S379 is conserved in Chk2 or-
thologs from mice, flies, and budding yeast; a threonine residue
is present in the equivalent site in the fission yeast Chk2 or-
tholog (Fig. 1E).
Ubiquitination assays were performed to determine if S379
was required for Chk2 ubiquitination. As seen in Fig. 1F,
wild-type Chk2 was ubiquitinated in vivo (top panel, lane 1),
and the kinase-inactive mutant (D368N) failed to be ubiquiti-
nated (lane 2). Interestingly, the S379A Chk2 mutant also
failed to be ubiquitinated in vivo (lane 3). In cells containing
DNA DSBs, ATM initiates Chk2 activation by phosphorylating
Chk2 on T68. T68 phosphorylation is required for efficient
oligomerization and subsequent auto-/transphosphorylation of
Chk2 at other regulatory sites, including T383/387. As seen in
Fig. 1F, both wild-type Chk2 and S379A, but not kinase-inac-
tive Chk2, were phosphorylated on T383/387. This suggests
that the S379A mutant of Chk2 retains kinase activity. This
conclusion is further supported by the fact that the electro-
phoretic mobility of S379A is slower than that of kinase-inac-
tive Chk2 (Fig. 1F, Flag3-Chk2 panel).
Several Chk2 mutants were also expressed in HEK-293 cells
to determine requirements for Chk2 ubiquitination (Fig. 1G).
Two kinase-inactive mutants (D368N and T383/387A) failed to
be ubiquitinated (lanes 3 and 5), demonstrating the impor-
tance of Chk2 kinase activity for ubiquitination. Wild-type
Chk2, T68A, and S516A are all kinase active, although the
encoding Flag3-Chk2 (WT, D368N, and S379A) and Myc-tagged ubiquitin. At 48 h posttransfection, cells were lysed and Chk2 proteins were
immunoprecipitated (IP) using an antibody specific for the Flag epitope. Ubiquitinated proteins were visualized by immunoblotting (IB) with an
antibody to the Myc tag. The Myc blots were then stripped and probed with an antibody specific for the Flag tag. Phosphorylation of Chk2 on
T383/387 and S379 was examined on total lysates using antibodies specific for these sites. (G) HEK-293 cells were transfected with expression
plasmids encoding Flag3-Chk2 (WT, D368N, T68A, T383/387A, or S516A) and Myc-tagged ubiquitin (Myc-Ub). Chk2 proteins were immuno-
precipitated using an antibody specific for the Flag epitope. Ubiquitinated proteins were visualized by immunoblotting with an antibody to the Myc
tag. The Myc blots were then stripped and probed with an antibody specific for the Flag tag.
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T68A mutant fails to be activated to the same extent as wild-
type Chk2 and S516A in response to DNA damage (3, 32, 33,
41, 57). As seen in Fig. 1G, wild-type Chk2, T68A, and S516A
were all ubiquitinated in vivo (lanes 2, 4, and 6), and the
ubiquitination of T68A was less that than that observed for
wild-type Chk2 and S516A. These findings underscore the im-
portance of both kinase activity and S379 phosphorylation for
Chk2 ubiquitination.
Phosphorylation of S379 is IR inducible and requires Chk2
kinase activity. To further characterize S379 phosphorylation,
an antibody specific for Chk2 phosphorylated on this residue
was generated (Fig. 1F and Fig. 2A). The antibody was then
used to monitor endogenous Chk2 phosphorylation in vivo. As
seen in Fig. 2B, endogenous Chk2 was inducibly phosphory-
lated on S379 within 30 minutes after IR treatment. Thus, S379
is a novel IR-inducible Chk2 phosphorylation site.
S379 is located within the activation loop of the Chk2 kinase
domain. Thus, mutation of S379 could impair the kinase activ-
ity of Chk2. Therefore, S379A was tested for its ability to
auto-/transphosphorylate in bacteria. As reported previously
(41), overproduction of Chk2 in bacteria promotes Chk2 oligo-
merization and auto-/transphosphorylation (Fig. 2C, lane 1),
whereas kinase-inactive Chk2 fails to be phosphorylated in
bacteria (Fig. 2C, lane 2). Importantly, the S379A mutant
displayed a shift in electrophoretic mobility and was phosphor-
ylated on T68, T383/387, and S516 in bacteria (Fig. 2C, lane 3),
demonstrating that mutation of S379 to alanine does not ren-
der Chk2 kinase inactive. The phosphorylation status of S379A
was also monitored in CHK2 null MEFs (16) to eliminate any
interactions between S379A and endogenous Chk2. As seen in
Fig. 2D, wild-type Chk2 was phosphorylated on T68, T383/387,
S379, and S516 (lane 1). Kinase-inactive Chk2 was phosphor-
ylated on T68 but not on residues that require Chk2 kinase
activity (T383/387 and S516). The finding that kinase-inactive
Chk2 was not detectably phosphorylated on S379 demonstrates
that phosphorylation of S379, like that of S516 and T383/387
but unlike that of T68, requires Chk2 kinase activity (Fig. 1F
and 2D, lane 2). Notably, S379A was phosphorylated on T68,
T383/387, and S516 in Chk2 null MEFs, demonstrating that
S379A retains kinase activity in vivo (Fig. 2D, lane 3).
Next, kinase assays were performed to measure the activa-
tion of S379A following exposure of cells to IR (Fig. 2E). The
kinase activity measured for S379A was similar to that of wild-
type Chk2 in the absence of IR. IR induced an approximate
2.3-fold activation in the kinase activity of wild-type Chk2,
whereas an approximate 1.5-fold activation in the kinase activ-
ity was measured for the S379A mutant. These results indicate
that mutation of S379 does not inactivate the catalytic activity
of Chk2 as does mutation of T383/387 that but mutation of
S379 does partially impair Chk2 activation by IR. Taken to-
gether, our results demonstrate that IR induces phosphoryla-
tion of Chk2 on S379, that S379 phosphorylation is dependent
on Chk2 kinase activity, and that phosphorylation of S379 is
required for Chk2 ubiquitination.
Chk2 ubiquitination catalyzed by Cul 1-containing E3 li-
gase. Next, experiments were performed to identify the E3
ubiquitin ligase responsible for Chk2 ubiquitination. Cullin-
containing E3 ligases comprise the largest family of ubiquitin
ligases in eukaryotic cells and consist of seven members (Cul 1,
Cul 2, Cul 3, Cul 4A, Cul 4B, Cul 5, and Cul 7) (38). We first
determined whether complexes between Chk2 and members of
the Cullin family could be detected in vivo. As seen in Fig. 3A,
cotransfection experiments revealed that Chk2 interacted with
Cul 1, 3, and 4B (lanes 1, 3, and 5) but not Cul 2, 4A, or 5
(lanes 2, 4, and 6). Next, dominant-negative forms of Cul 1, 3,
and 4B were tested for their ability to block Chk2 ubiquitina-
tion in vivo (12, 36, 43). As seen in Fig. 3B, ubiquitination of
wild-type Chk2 was blocked by a dominant-negative Cul 1
mutant (lane 4) but not dominant-negative forms of Cul 3 or
4B (lanes 5 and 6). As expected, kinase-inactive Chk2 (lanes 7
to 10) and S379A (lanes 11 to 14) were not ubiquitinated (Fig.
3B) and did not associate with Cul 1 (Fig. 4A, lanes 2 and 3) in
vivo. Finally, assays were performed in vitro to monitor the
ability of Cul 1-, 3-, and 4B-containing complexes to catalyze
Chk2 ubiquitination. As seen in Fig. 4B, only Cul 1-containing
complexes ubiquitinated Chk2 in vitro (lane 4). Neither kinase-
inactive Chk2 (lanes 7 to 9) nor S379A (lanes 10 to 12) was
ubiquitinated in vitro. These findings indicate that a Cul 1-con-
taining E3 ligase is responsible for Chk2 ubiquitination in vivo.
Role of Chk2 S379 phosphorylation. Endogenous Chk2 pro-
tein levels were monitored in both the presence and absence of
DNA DSBs in HEK-293 cells (Fig. 5A). In the presence of
cycloheximide, Chk2 levels remained stable for at least 2 h in
mock-irradiated cells (Fig. 5A, lanes 1 to 4 and 9 to 12). IR
induces Chk2 phosphorylation, which, in turn, causes Chk2 to
migrate more slowly on SDS gels (Fig. 5A, lanes 5 to 8).
Quantitation of Western blotting results suggested that IR also
promoted Chk2 turnover. However, when cell lysates were
treated with  phosphatase prior to Western blotting (Fig. 5A,
lanes 13 to 16), Chk2 was observed to be stable in IR-treated
cells. These results demonstrate that the Chk2 antibody used
for Western blotting inefficiently recognizes phosphorylated
forms of Chk2 and that the half-life of endogenous Chk2 is not
dramatically altered in cells exposed to IR. Next, the half-life
of ectopically expressed Chk2 was measured in HEK-293 cells,
as wild-type Chk2 is ubiquitinated when overproduced in these
cells (Fig. 1A and F). HEK-293 cells expressing wild-type and
mutant forms of Flag-tagged Chk2 were incubated with cyclo-
heximide, and Chk2 levels were monitored by Western blotting
using an antibody specific to the Flag tag. As seen in Fig. 5B,
levels of wild-type and mutant Chk2 proteins remained stable
over the 4-h incubation period.
Protein ubiquitination regulates a plethora of biological ac-
tivities in addition to proteosome-mediated degradation, in-
cluding protein-protein interactions, enzymatic activity, and
intracellular localization. Therefore, we tested whether S379
phosphorylation was required for Chk2 signaling. Chk2 is a
critical regulator of DNA damage-induced apoptosis, particu-
larly in response to agents that induce DNA DSBs (16, 19, 45,
46, 51, 54). To test whether S379 phosphorylation was required
for Chk2-mediated apoptosis, U2OS cells stably expressing
wild-type and mutant forms of Chk2 in the same genetic locus
were generated. A FRT site was first introduced into U2OS
cells to generate the U2OS/FRT parental line. Plasmids en-
coding Myc3-Chk2-WT, Myc3-Chk2-D368N, and Myc3-Chk2-
S379A were then cotransfected with the Flp recombinase from
S. cerevisiae to generate the U2OS/FRT stable cell lines ex-
pressing Myc3-Chk2 (WT and mutants) at the same locus.
Densitometry analysis revealed that the Myc3-Chk2 proteins
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FIG. 2. Phosphorylation and kinase activity of Chk2 S379A. (A) Lysates of HEK-293 cells expressing Flag3-Chk2-WT or Flag3-S379A were
resolved by SDS-PAGE and blotted with an antibody specific for Chk2 phosphorylated on S379. The blot was then stripped and reprobed with an
antibody specific for the Flag epitope. (B) Lysates from HEK-293 cells that had been mock irradiated (lane 1) or exposed to 10 Gy IR (lane 2)
were resolved by SDS-PAGE and blotted with an antibody specific for Chk2 phosphorylated on S379 and an antibody specific for Chk2.
(C) His6-Chk2-WT, -D368N, and -S379A were purified from bacteria. Matched amounts of protein were resolved by SDS-PAGE and blotted with
the indicated antibodies. (D) Lysates from Chk2 null MEFs expressing Flag3Chk2-WT, -D368N, or -S379A were incubated with an antibody
specific for the Flag epitope. Precipitates were resolved by SDS-PAGE and blotted with the indicated phospho-specific antibodies. The phospho-
specific blots were then stripped and reprobed with an antibody specific for the Flag tag. (E) Myc3-tagged Chk2 proteins (WT and S379A) were
precipitated from U2OS/FRT stable lines 30 min after mock irradiation () or exposure to 10 Gy IR (). The precipitated Chk2 proteins were
tested for their ability to phosphorylate GST-Cdc25C(200–256) in vitro. 32P-labeled GST-Cdc25C(200–256) was quantified using a Storm Imager.
Error bars indicate the standard errors of the means for triplicate reactions performed for each Chk2 protein.
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were expressed at approximately twofold the level of endoge-
nous Chk2 in the U2OS/FRT lines (Fig. 6A).
Apoptosis was assayed by treating the U2OS/FRT stable cell
lines with etoposide and analyzing DNA content by flow cy-
tometry (45). As seen in Fig. 6B, cells expressing D368N or
S379A were less susceptible to etoposide-induced apoptosis
than were parental cells or cells expressing wild-type Chk2.
These results demonstrate that both kinase activity and S379
FIG. 3. Chk2 ubiquitination by Cul 1 E3 ligase complex. (A) HEK-293 cells were transfected with plasmids encoding Flag3-Chk2-WT and the
indicated Myc-tagged Cullin proteins for 48 h. Lysates were prepared and either resolved directly by SDS-PAGE (bottom panel) or first incubated
with an antibody specific for the Flag epitope (top panel), and precipitates were resolved by SDS-PAGE. Western blotting was performed with Myc
antibody to detect tagged Cullin proteins and with Flag antibody to detect precipitated Flag3-Chk2. (B) HEK-293 cells were transfected with
plasmids encoding hemagglutinin-tagged ubiquitin (HA-Ub), Myc3-Chk2, and dominant-negative forms of Cul 1, 3, and 4B. Myc3-Chk2 was
immunoprecipitated (IP), and ubiquitinated Chk2 was examined by Western blotting (IB) with HA-specific antibody. The blot was then stripped
and blotted with Myc antibody. Total lysates were examined for Cullin levels by Western blotting with a Flag-specific antibody.
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phosphorylation are required for the proapoptotic effector
function of Chk2.
The phosphorylation status of endogenous Chk2 was moni-
tored in each of the U2OS cell lines to determine whether
D368N or S379A interfered with activation of endogenous
Chk2. Chk2 activation can be determined indirectly by moni-
toring its mobility on SDS gels as well as by S516 phosphory-
lation. Part of the self-sustaining Chk2 activation cycle involves
auto-/transphosphorylation of Chk2 on S516 as well as other
residues, and this causes Chk2 to migrate more slowly on SDS
gels. Phosphorylation of T68 is catalyzed by kinases in addition
to Chk2 (3, 57), and as seen in Fig. 6C, IR induced the phos-
phorylation of endogenous Chk2 on T68 in each cell line (lanes
5 to 8). However, endogenous Chk2 failed to undergo mobility
shifts (Fig. 6C, lane 7) and to be phosphorylated on S516 (Fig.
6D, lanes 8 and 9) in cells expressing D368N. This suggests that
the kinase-inactive Chk2 mutant functions in a dominant-neg-
ative manner. In contrast, the activation and phosphorylation
of endogenous Chk2 appeared normal in cells expressing
S379A. Thus, expression of D368N blocked activation of en-
dogenous Chk2, and this likely accounts for its ability to block
DNA damage-induced apoptosis in U2OS cells. In contrast,
results obtained for S379A indicate that this mutant interferes
with pathways downstream of endogenous Chk2 activation.
DISCUSSION
In cells containing DNA DSBs, ATM initiates Chk2 activa-
tion by phosphorylating Chk2 on T68. This leads to Chk2
oligomerization, which facilitates Chk2 phosphorylation at ad-
ditional sites through an auto-/transphosphorylation mecha-
nism. Here we demonstrate that auto-/transphosphorylation of
Chk2 on S379 also leads to its ubiquitination by a Cul 1-con-
taining E3 ligase. To recruit specific substrates, Cul 1 binds the
Skp1 adaptor protein (13, 44, 56). Skp1 then binds an F box
protein, which in turn recruits substrates for ubiquitination.
Additional studies will be required to identify the F box protein
that targets Chk2 to the Cul 1 complex. In general, the recruit-
FIG. 4. Chk2 is ubiquitinated in vitro by a Cul 1-containing E3 ligase. (A) HEK-293 cells were transfected with plasmids encoding Flag3-Chk2
(WT, D368N, or S379A) and Myc-Cul 1. Flag3-tagged proteins were isolated using Flag-agarose, and precipitates were examined for the presence
of Myc-Cul 1 by Western blotting with antibodies specific for the Myc and Flag tags (top panel). Levels of Myc-Cul 1 were determined by Western
blotting total cell lysates (bottom panel). (B) Chk2 proteins were purified as Flag-tagged proteins as described in Materials and Methods and
incubated in vitro with purified ubiquitin, E1 (Ube1), and E2 (UbcH5c) in ubiquitin reaction buffer at 37°C for 1 h. Reactions were resolved by
SDS-PAGE and subjected to Western blotting (IB) with antibodies specific for ubiquitin (top panel) or Flag (bottom panel).
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ment of substrates to the Skp1-Cul 1-F box complex requires
that the substrate first be phosphorylated. In the case of Chk2,
S379 phosphorylation is required for its interactions with Cul 1
and its subsequent ubiquitination. Mutants of Chk2 that failed
to be phosphorylated on S379 (kinase-inactive Chk2 and the
S379A mutant) did not associate with Cul 1 and were not
ubiquitinated in vivo. This suggests that S379 phosphorylation
may regulate interactions between the Cul-containing E3 li-
gase complex and Chk2. We were unable to detect significant
changes in the half-life of Chk2 after its ubiquitination, con-
sistent with studies reporting that Chk2 remains stable during
a DNA damage checkpoint response (4, 5, 28, 54). Kass et al.
recently reported that dephosphorylation on S456 is necessary
for Chk2 ubiquitination and that ubiquitination regulates Chk2
turnover (22). Differences in results between these studies may
be due to differences in the cell lines used or the type or
intensity of DNA damage.
Although proteasome-dependent degradation of ubiquiti-
nated proteins is the best-characterized function for this mod-
ification, there have been several additional functions reported
for protein ubiquitination over the past few years (21, 39). In
particular, both Brca1 and RNF8 are E3 ubiquitin ligases that
translocate to sites of DNA damage and ubiquitinate proteins
to recruit additional proteins to sites of damage and to activate
signaling pathways (18, 24, 30, 49). It has not been determined
when Chk2 becomes ubiquitinated. The adaptor protein
MDC1 recruits RNF8 to damaged chromatin in a phosphory-
lation-dependent manner, and the ubiquitin-interacting motif-
containing protein RAP80 mediates the localization of Brca1
to DNA damage foci (18, 30, 49, 50). MDC1 associates with
phosphorylated Chk2 at foci following DNA damage and con-
tributes to Chk2-mediated apoptosis (27). It will be important
to determine if Chk2 ubiquitination recruits Chk2 to foci by,
for example, binding a ubiquitin-interacting motif-containing
protein such as RAP80 at sites of DNA damage. This would
enable Chk2 to interact with MDC1 and to phosphorylate
Brca1 (26, 27). Alternatively, Chk2 may become ubiquitinated
after its translocation to foci. Chk2 has also been shown to
associate with USP28, a deubiquitinating enzyme, but the func-
tional significance of this interaction requires further study
(55).
The initial activation of Chk2 involves its translocation to
FIG. 5. Ubiquitination of Chk2 does not affect Chk2 stability. (A) HEK-293 cells were treated with cycloheximide and then either mock or
gamma irradiated and collected at the indicated times post-IR. Lysates were incubated in the absence or presence of  phosphatase. Chk2 protein
levels were monitored by Western blotting using a Chk2 monoclonal antibody. An antibody specific for actin was used to verify similar loading in
each lane. Densitometry analysis was performed using Image J software and normalized to the level of actin. Chk2 protein levels at each time point
are shown relative to those in mock-irradiated samples (time zero is set at 1.0). (B) Flag3-Chk2 proteins (WT, D368N, and S379A) were expressed
in HEK-293 cells. Cells were cultured in the presence of cycloheximide and collected at the indicated time points. Flag3-Chk2 protein levels were
examined using an anti-Flag antibody. Densitometry analysis was performed as for panel A.
5882 LOVLY ET AL. MOL. CELL. BIOL.
 o
n








FIG. 6. Phosphorylation of S379 in activation of Chk2 and apoptosis induction. (A) U2OS/FRT parental cells were stably transfected with
plasmids encoding Myc3-Chk2-WT, Myc3-Chk2-D368N, or Myc3-Chk2-S379A as described in Materials and Methods. Lysates were blotted with
an antibody against Chk2, and the relative expression level of Myc3-Chk2 versus endogenous Chk2 for each cell line was quantified by
chemiluminescence using a Storm Imager; the ratio of ectopic to endogenous Chk2 expression is indicated. (B) U2OS/FRT parental and
Chk2-expressing cells were treated with etoposide for the indicated times. The percentage of cells containing sub-2N DNA content was assessed
by propidium iodide staining and fluorescence-activated cell sorter analysis. Error bars denote standard errors of the means (n 	 4). (C and D)
U2OS/FRT parental and Chk2-expressing cells were exposed to IR. Lysates were prepared and Western blotting was performed with the indicated
antibodies.
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sites of DNA damage. However, this relocalization is transient
and Chk2 becomes rapidly redistributed throughout the nu-
cleus in order to carry out its signaling function (29). The fact
that the S379A mutant was not ubiquitinated and was impaired
in its ability to induce apoptosis in cells with DNA DSBs
suggests that Chk2 ubiquitination and signaling may be cou-
pled. Expression of a kinase-inactive mutant of Chk2 blocked
phosphorylation of endogenous Chk2 and impaired apoptosis
in cells with DNA DSBs. Thus, kinase-inactive Chk2 may func-
tion as a dominant-negative mutant by oligomerizing with en-
dogenous Chk2 and thereby preventing subsequent auto-/
transphosphorylation events. In contrast, the S379A mutant
did not detectably alter endogenous Chk2 phosphorylation.
This suggests that proximal Chk2 activation events (Chk2 oligo-
merization and auto-/transphosphorylation) were not per-
turbed in S379A-expressing cells. However, the ability of DNA
DSBs to induce apoptosis was impaired in cells expressing the
S379A mutant. This may indicate that ubiquitination of Chk2
is an important step in licensing Chk2 for downstream signal-
ing. Additional studies will be required to elucidate how ubiq-
uitination couples Chk2 to its downstream substrates.
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